FY22 - It's all to play for here!, page-11

I think if they get ONE approval (satisfying the FDA's demands re: manufacturing consistency and quality to ensure potency), they will get multiple/all of them eventually where there is a significant result shown.

New technology, new questions as to just how it works and just how we can be certain it will always do what MSB says it does, with the FDA making their standards for this new science up on the fly (while kids and < 65s are croaking daily, but hey...what can you do?).

We all know the FDA are a bunch of hypocritical POSs, what with that recent Alzheimer's disease debacle, and the resignation of a number of their experts as fallout from their clearly corrupt decision, but they are doing here what they are supposed to be doing always (albeit what they fail to do in most other cases it seems...).

Assuming that Rem-L and Rex-L are manufactured using the same techniques/technology/potency assays, etc., presumably even in the same facilities and by the same MSB/Lonza team members, all that SHOULD matter is what the RCT results indicate the MSCs can accomplish.

I will likely buy a bit more under 1.40-50 as well if it goes down there, may as well keep averaging down. Salve for my bruised ego and pocketbook...